THE DUBERSTEIN GROUP INC. for PHRMA INC.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Impact of sequestration on FDA user fees - Proposed legislation re this issue; Executive Branch action re this issue.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN CHAMPLIN | — |
Taxation/Internal Revenue Code TAX
Tax extenders, including research and development tax credit - Draft legislation re this issue.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL P MEYER | — |
Medicare/Medicaid MMM
Medicare Part D. Sustainable growth rate - HR 2810, Medicare Patient Access and Quality Improvement Act of 2013; HR 4015, SGR Repeal and Medicare Provider Payment Modernization Act of 2014; HR 4302, Protecting Access to Medicare Act of 2014; S 2000, SGR Repeal and Medicare Provider Payment Modernization Act of 2014;S 2122, Responsible Medicare SGR Repeal and Beneficiary Access Improvement Act of 2014.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL P MEYER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.